Skip to main content
Home

User menu controls

  • Search
  • Member Login
  • Menu

Search

Main navigation

  • About NPC
    • Member Companies
    • Get Involved
    • NPC Staff
    • Fellowship Program
    • Contact Us
  • Issues
    • Evidence
      • Using Real-World Evidence
      • Standards for Real-World Evidence
        • CER Collaborative
        • GRACE
      • Accessing Data
      • Communicating Evidence
    • Value
      • Defining Value
      • Measuring Value
        • Value Assessment Frameworks
    • Access to Medicines
      • Health Benefit Design
        • Impact of Benefit Restrictions
        • Copayment Design
        • VBID: Value-Based Insurance Design
        • High-Deductible Health Plans
        • Individual Treatment Effects
      • Provider Reimbursement
        • Risk-Sharing Agreements
        • Bundled Payments
        • Clinical Care Pathways
        • Accountable Care Organizations
        • Quality Measurement
    • Innovation
      • Spending Wisely on Health
      • Paying Differently for Health
    • Issue Archives
      • Aging
      • Cultural Diversity
      • Direct-to-Consumer Advertising
      • Disease Management & Medicaid Health Outcomes Management
      • Drug Spending Trends
      • Health & Productivity
      • Integrated Care
      • Medicaid Plan Pharmaceutical Resources
      • Medicare Part D Drug Benefit
      • Medication Compliance/Adherence
  • Media
    • Press Releases
    • CER Daily Newsfeed®
    • E.V.I.dently® Newsletter
    • Videos & Podcasts
    • Infographics
    • Commentary
    • Research Library
    • Blog
    • Events & Education

Breadcrumb

  1. Home
  2. Issues
  3. Issue Archives

Drug Spending Trends

Increased spending on prescription drugs is often attributed to higher prices for existing and new drugs. However, increases in spending also are determined by the volume of prescription drugs taken by patients, which is defined as the number of prescriptions and the number of days for which a given prescription provides therapy.

Research supported by the National Pharmaceutical Council in the early 2000s developed the methods needed to identify the specific price and volume factors responsible for increased drug spending. This research found that increased use of prescription drugs due to better diagnosis of disease, new medical recommendations for treatment, and in some cases, newer, more effective medicines may play a larger role than increases in price in explaining increased spending trends.

Related Resources

U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
newspaper headlines
ICER Pricing Report: Creating a Dialogue or Just Playing for Headlines?
Robert Dubois, MD, PhD, NPC Interim President and Chief Executive Officer
Forging a Path Toward a More Stable and Patient-Centric Health System in 2021

Share

Sign up for our Newsletters

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently® and the CER Daily Newsfeed®.

Sign Up

Let's stay in touch.

Sign up for our newsletter

Footer menu 1

  • Evidence
  • Value
  • Access
  • Innovation
  • About NPC
  • Research Library
  • Member Login
  • Sitemap

Footer menu 2

  • CER Daily Newsfeed®
  • E.V.I.dently® Newsletter
  • Blog

1717 Pennsylvania Avenue, NW
Suite 800
Washington, DC 20006

Phone: (202) 827-2100
info@npcnow.org

  • Facebook
  • LinkedIn
  • Twitter
  • Scribd
  • YouTube

The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. To learn more, visit our issue pages, research library and educational offerings.

© 2013-2020 NPC. All rights reserved.

Footer Bottom

  • Contact Us
  • Privacy Policy
  • Terms of Use